Gladius Capital Management LP Eagle Pharmaceuticals, Inc. Transaction History

Gladius Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Dec 18, 2023	BUY	$15.21 - $22.88 $1,627 - $2,448	107 Added 8.14%	1,421 $22,000
Q3 2023 Oct 10, 2023	BUY	$15.21 - $22.88 $1,627 - $2,448	107 Added 8.14%	1,421 $23,000
Q2 2023 Dec 18, 2023	SELL	$17.74 - $31.87 $1,898 - $3,410	-107 Reduced 7.53%	1,314 $25,000
Q2 2023 Aug 08, 2023	BUY	$17.74 - $31.87 $4,647 - $8,349	262 Added 24.9%	1,314 $26,000
Q1 2023 Dec 18, 2023	SELL	$25.06 - $34.09 $9,247 - $12,579	-369 Reduced 25.97%	1,052 $29,000
Q1 2023 May 09, 2023	SELL	$25.06 - $34.09 $50 - $68	-2 Reduced 0.19%	1,052 $30,000
Q4 2022 Dec 18, 2023	SELL	$24.98 - $39.77 $9,167 - $14,595	-367 Reduced 25.83%	1,054 $30,000
Q4 2022 Feb 02, 2023	SELL	$24.98 - $39.77 $1,823 - $2,903	-73 Reduced 6.48%	1,054 $31,000
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $29,775 - $53,104	1,127 New	1,127 $30,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.